Ranking of well-known pharmaceutical companies announced

Major pharmaceutical companies have successively released their latest semi-annual reports, and new sales rankings have arrived

01 Top 25 Pharmaceutical Companies in Sales Ranking

Recently, according to the latest analysis of the pharmaceutical sales of various pharmaceutical companies from 2016 to 2020 by the WeChat public account "Pharmaceuticals", the sales of multinational pharmaceutical companies from 2016 to 2020 are ranked.

According to the ranking, the total sales volume in the past five years shows that Johnson & Johnson, Roche, Pfizer, Novartis, Bayer, Merck, Sanofi, GlaxoSmithKline, Fresenius, and AbbVie are among the top ten

It can be seen from the sales of the past five years that Johnson & Johnson has been in the forefront of the rankings in recent years and its pharmaceutical business is strong

Prior to this, Johnson & Johnson released its second-quarter financial report.

Johnson & Johnson's business income mainly includes three major segments: pharmaceuticals, medical devices, and consumer healthcare

According to the Insight database, Usnuzumab has the most impressive performance, with sales reaching 7.

02 Roche, firmly ranked second

From the 2017-2020 sales data, it can be seen that Roche's sales have been in the forefront in the past few years, and the total sales in the past five years have been ranked second

When it comes to Roche, the first thing that comes to mind is the "troika".

Among them, the multiple sclerosis (MS) drug Ocrevus will maintain a 24% growth in 2020, with sales reaching 4.

According to Roche’s first half of 2021 financial report, overall revenue increased by 8% year-on-year to 30.

03 Novartis's ranking rises

Novartis ranked third in sales in 2020 with a total of 49.

In Novartis's 2020 annual report, net sales increased by 3% year-on-year to US$48.

Novartis's 2021Q2 global revenue increased by 9% year-on-year to US$12.

The development of the Chinese market is naturally inseparable from the influence of policies such as national procurement

At present, Novartis has alleviated the sales pressure brought about by national procurement and other policies by increasing the launch of new drugs, but the specific effect still depends on the later development

04 Pfizer sales decline

In the past five years of sales, Pfizer's overall sales in 2020 has fallen sharply
.

Prior to this, the US "Pharmaceutical Managers Magazine" announced the TOP50 list of global pharmaceutical companies in 2021.
Pfizer, which fell from the top to the third in 2020, once again fell sharply to No.
8 this year
.

Expired patented drugs have had a greater impact on Pfizer’s sales.
In 2007, the patent of Pfizer’s second best-selling drug Luo Huoxi expired; in 2011, the patent of Pfizer’s first best-selling drug, Lipitor, expired; in 2012 , Viagra patent expired
.
In 2018, Pfizer announced that it would split its business into three parts: biopharmaceuticals, Pfizer Pertron and health drugs.
Pfizer Pertron is a global business group focused on brand-name drugs and generic drugs with expired patents, including 20 expired patents.
Brands of solid oral preparations, including Lerica, Lipitor, Luohuxi, Viagra and Celebrex, as well as some generic drugs
.

Pfizer announced its performance report on February 2, announcing that it has completely completed the divestiture of Puqiang and has become a company focused on innovative biopharmaceutical business
.

In 2020, Pfizer's annual revenue was 41.
908 billion U.
S.
dollars, compared with 41.
172 billion U.
S.
dollars in the same period last year
.
Excluding the revenue from Puqiang's business, it increased by 2% year-on-year, and after deducting the revenue of US$154 million from the consumer health care business and the new crown vaccine BNT162b2, just looking at the biopharmaceutical business, it achieved a year-on-year increase of 7%
.